{
    "clinical_study": {
        "@rank": "65594", 
        "arm_group": {
            "arm_group_label": "Preoperative chemoradiation", 
            "arm_group_type": "Experimental", 
            "description": "Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide"
        }, 
        "brief_summary": {
            "textblock": "Trial to determine the safety of neoadjuvant treatment with concurrent temozolomide and\n      radiation therapy, followed by surgery and then further temozolomide."
        }, 
        "brief_title": "Preoperative Chemoradiation for Glioblastoma", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "Prior to any definitive treatment and after enrollment, the patient will undergo\n      stereotactic biopsy of the lesion to confirm the histology of the lesion and to determine\n      methylated methylguanine methyltransferase (MGMT) status. Standard image-guided stereotactic\n      technique will be used. Patients will be treated with conformal radiation therapy.\n      Temozolomide will be given from the day prior to radiation therapy through the last day of\n      radiation therapy. 4-6 weeks after radiation therapy the patient will undergo craniotomy and\n      maximal safe resection. Temozolomide will continue beginning 4 weeks after surgery.\n\n      Imaging:\n\n      MRI within 2 weeks prior to the start of the protocol. MRI at 4 weeks after chemoradiation\n      therapy and prior to surgery. MRI within 48 hours after surgery.\n\n      MRI after every 2 cycles of chemotherapy and then every 2 months until progression, up to 2\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  MRI lesions of the brain that have a high probability of being glioblastoma  in a\n             potentially resectable location in the brain (the primary study population)\n\n          -  WHO performance status 0-2 (to allow comparison to historical controls)\n\n          -  Adequate hematological parameters: (for safety because of neutropenia from the\n             temozolomide)\n\n          -  Consent can be obtained from the patient, and if the patient cannot give consent then\n             from the medical power of attorney and if one is not assigned, then the nearest\n             relative (required to obtain consent)\n\n          -  Able to have MRI scans (secondary endpoint is MRI scan characteristics)\n\n          -  Willing to have radiation treatment at a participating center (homogeneity of\n             treatment parameters)\n\n          -  Ages 18-80\n\n        Exclusion Criteria:\n\n          -  Unresectable tumor\n\n          -  Absolute neutrophil count (ANC) less than 1,200/\u03bcL\n\n          -  Hemoglobin less than 9.0g/dL\n\n          -  Platelet count less than 100,000/\u03bcL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092038", 
            "org_study_id": "TGH0001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Preoperative chemoradiation", 
                "description": "Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temodar"
            }, 
            {
                "arm_group_label": "Preoperative chemoradiation", 
                "description": "Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.", 
                "intervention_name": "partial brain irradiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Preoperative chemoradiation", 
                "description": "will be assessed for tumor type and tumor markers", 
                "intervention_name": "stereotactic biopsy of brain tumor", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Preoperative chemoradiation", 
                "description": "maximal safe resection", 
                "intervention_name": "craniotomy and tumor resection", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glioblastoma", 
            "temozolomide", 
            "radiation therapy", 
            "radiotherapy", 
            "surgery", 
            "pre-operative", 
            "neoadjuvant"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33606"
                }, 
                "name": "Tampa General Hospital"
            }, 
            "investigator": {
                "last_name": "Lawrence Berk, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma", 
        "overall_contact": {
            "email": "dafife@tgh.org", 
            "last_name": "Denise Fife, RN", 
            "phone": "813-844-7829"
        }, 
        "overall_contact_backup": {
            "email": "debraharris@tgh.org", 
            "last_name": "Debra Harris", 
            "phone": "813-844-3463"
        }, 
        "overall_official": {
            "affiliation": "Tampa General Hospital", 
            "last_name": "Lawrence Berk, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "comparison of toxicity related to experimental treatment to historical local controls", 
            "measure": "toxicity of treatment per    Common Toxicity Criteria for Adverse Effects V3.0", 
            "safety_issue": "Yes", 
            "time_frame": "up to up to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092038"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "determination of the feasibility of using standard MGMT activity measurement techniques on stereotactic specimens and comparison of the results with the results from the full resection.", 
                "measure": "Feasibility of measurement of O(6)-Methylguanine-DNA methyltransferase (MGMT) activity on stereotactic samples", 
                "safety_issue": "No", 
                "time_frame": "at enrollment"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }
        ], 
        "source": "Tampa General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tampa General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}